Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Duyuru • Oct 30
Provexis plc to Report Q2, 2026 Results on Oct 30, 2025 Provexis plc announced that they will report Q2, 2026 results on Oct 30, 2025 Duyuru • Sep 30
Provexis plc, Annual General Meeting, Nov 21, 2025 Provexis plc, Annual General Meeting, Nov 21, 2025. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom Reported Earnings • Oct 01
Full year 2024 earnings released: EPS: UK£0 (vs UK£0 in FY 2023) Full year 2024 results: EPS: UK£0 (in line with FY 2023). Revenue: UK£802.0k (up 106% from FY 2023). Net loss: UK£586.2k (loss widened 52% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 30% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings. Duyuru • Oct 01
Provexis plc, Annual General Meeting, Oct 25, 2024 Provexis plc, Annual General Meeting, Oct 25, 2024. Location: the offices of allenby capital limited, 5th floor, 5 st helens place, ec3a 6ab, london United Kingdom New Risk • Jul 16
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m (UK£598k revenue, or US$775k). Minor Risks Latest financial reports are more than 6 months old (reported September 2023 fiscal period end). Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.2m market cap, or US$17.6m). New Risk • Mar 30
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£428k free cash flow). Share price has been highly volatile over the past 3 months (22% average weekly change). Revenue is less than US$1m (UK£598k revenue, or US$755k). Minor Risks Shareholders have been diluted in the past year (2.0% increase in shares outstanding). Market cap is less than US$100m (€16.5m market cap, or US$17.8m). Reported Earnings • Oct 01
Full year 2023 earnings released: EPS: UK£0 (vs UK£0 in FY 2022) Full year 2023 results: EPS: UK£0 (in line with FY 2022). Revenue: UK£389.9k (down 8.5% from FY 2022). Net loss: UK£385.2k (loss widened 72% from FY 2022). Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Duyuru • Sep 30
Provexis plc, Annual General Meeting, Oct 26, 2023 Provexis plc, Annual General Meeting, Oct 26, 2023, at 11:30 Coordinated Universal Time. Location: Allenby Capital Limited, 5th Floor, 5 St Helen's Place London, United Kingdom Agenda: To consider and approve That the annual financial statements of the Company for the year ended 31 March 2023 and the reports of the Directors and auditors thereon be received; to consider and approve the Shipleys LLP be re-appointed as auditors of the Company to hold office from the conclusion of the Annual General Meeting until the conclusion of the next Annual General Meeting of the Company; to consider that the Directors be authorised to agree the auditors' remuneration and to consider and approve other business matters. New Risk • Jul 02
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue is less than US$1m (UK£394k revenue, or US$501k). Minor Risks Latest financial reports are more than 6 months old (reported September 2022 fiscal period end). Market cap is less than US$100m (€14.8m market cap, or US$16.2m). Reported Earnings • Dec 31
First half 2023 earnings released: EPS: UK£0 (vs UK£0 in 1H 2022) First half 2023 results: EPS: UK£0 (in line with 1H 2022). Revenue: UK£179.4k (down 15% from 1H 2022). Net loss: UK£155.8k (loss widened 20% from 1H 2022). Over the last 3 years on average, earnings per share has increased by 28% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth. Board Change • Nov 16
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. No independent directors (3 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Duyuru • Oct 14
Provexis plc Announces Directorate Change Provexis, announced the resignation of Frédéric Boned, a Non-executive Director of the Company, with immediate effect. Frédéric Boned joined the Board of Provexis as a Non-executive Director in July 2018, at which point he was EMEA Vice President of DSM's Human Nutrition & Health business, a part of DSM Nutritional Products. Frédéric, who is currently Regional Vice President Health Nutrition & Care North America at DSM, has announced his resignation from DSM with effect from 15 October 2022. Reported Earnings • Oct 01
Full year 2022 earnings released Full year 2022 results: Revenue: UK£426.2k (down 16% from FY 2021). Net loss: UK£224.3k (loss narrowed 34% from FY 2021). Duyuru • Jun 22
Provexis plc Announces the Filing of New Patent Application Provexis plc announced the filing of a new patent application relating to the use of Fruitflow to confer health benefits in modulating the gut microbiome of humans. This follows the completion of a successful human study, the results of which (as stated in the patent application) strongly support the use of Fruitflow for modulating gut microbiota to confer a number of health benefits. Board Change • Apr 27
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 2 highly experienced directors. No independent directors (4 non-independent directors). Chief Scientific Officer, Member of Scientific Advisory Board & Executive Director Niamh O’Kennedy was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Duyuru • Nov 16
Provexis plc Announces Exclusive Distribution Agreement for Chinese CBEC Provexis announced it has entered into a distribution agreement with a company ('the Distributor') which will act as the distributor for Fruitflow+ Omega-3 in China, exclusively through the Chinese Cross-Border e-commerce ('CBEC') channel. CBEC regulations include a waiver of the existing Chinese pre-importation registration requirements on specified categories of products, permitting overseas exporters to sell consumer goods directly to Chinese consumers through certain registered e-commerce platforms. The agreement announced grants the Distributor exclusive rights to import, market and sell the Company's Fruitflow+ Omega-3 dietary supplement product in China through the CBEC channel, with immediate effect. The Distributor will purchase Fruitflow+ Omega-3 as required from the Company, and the Distributor will then market and sell Fruitflow+ Omega-3 in China through its existing network of e-commerce and other sales channels. The Company has recently completed a redesign of the existing Fruitflow+ Omega-3 packaging, to include a new single blister pack format, with this new packaging having been optimised for sales through CBEC by the Distributor in China. Reported Earnings • Oct 01
Full year earnings released - €0.0002 loss per share Over the last 12 months the company has reported total losses of UK£406.2k, with losses narrowing by 21% from the prior year. Total revenue was UK£347.9k over the last 12 months, up 7.9% from the prior year. 
